Current and historical daily PE Ratio for Pharma Equity Group A/S (
OCSE:PEG
) from 2003 to Jun 13 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Pharma Equity Group A/S stock (OCSE:PEG) PE ratio as of Jun 13 2024 is 0.
More Details
Pharma Equity Group A/S (OCSE:PEG) PE Ratio (TTM) Chart
Pharma Equity Group A/S (OCSE:PEG) PE Ratio (TTM) Historical Data
View and export this data going back to 2003. Start your Free Trial
Total 1277
- 1
- 2
- 3
- 4
- 5
- 6
- 15
| Pharma Equity Group A/S PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-13 | At Loss | 2024-04-05 | At Loss |
| 2024-06-12 | At Loss | 2024-04-04 | At Loss |
| 2024-06-11 | At Loss | 2024-04-03 | At Loss |
| 2024-06-10 | At Loss | 2024-04-02 | At Loss |
| 2024-06-07 | At Loss | 2024-03-27 | At Loss |
| 2024-06-06 | At Loss | 2024-03-26 | At Loss |
| 2024-06-04 | At Loss | 2024-03-25 | At Loss |
| 2024-06-03 | At Loss | 2024-03-22 | At Loss |
| 2024-05-31 | At Loss | 2024-03-21 | At Loss |
| 2024-05-30 | At Loss | 2024-03-20 | At Loss |
| 2024-05-29 | At Loss | 2024-03-19 | At Loss |
| 2024-05-28 | At Loss | 2024-03-18 | At Loss |
| 2024-05-27 | At Loss | 2024-03-15 | At Loss |
| 2024-05-24 | At Loss | 2024-03-14 | At Loss |
| 2024-05-23 | At Loss | 2024-03-13 | At Loss |
| 2024-05-22 | At Loss | 2024-03-12 | At Loss |
| 2024-05-21 | At Loss | 2024-03-11 | At Loss |
| 2024-05-17 | At Loss | 2024-03-08 | At Loss |
| 2024-05-16 | At Loss | 2024-03-07 | At Loss |
| 2024-05-15 | At Loss | 2024-03-06 | At Loss |
| 2024-05-14 | At Loss | 2024-03-05 | At Loss |
| 2024-05-13 | At Loss | 2024-03-04 | At Loss |
| 2024-05-08 | At Loss | 2024-03-01 | At Loss |
| 2024-05-07 | At Loss | 2024-02-29 | At Loss |
| 2024-05-06 | At Loss | 2024-02-28 | At Loss |
| 2024-05-03 | At Loss | 2024-02-27 | At Loss |
| 2024-05-02 | At Loss | 2024-02-26 | At Loss |
| 2024-05-01 | At Loss | 2024-02-23 | At Loss |
| 2024-04-30 | At Loss | 2024-02-22 | At Loss |
| 2024-04-29 | At Loss | 2024-02-21 | At Loss |
| 2024-04-26 | At Loss | 2024-02-20 | At Loss |
| 2024-04-25 | At Loss | 2024-02-19 | At Loss |
| 2024-04-24 | At Loss | 2024-02-16 | At Loss |
| 2024-04-23 | At Loss | 2024-02-15 | At Loss |
| 2024-04-22 | At Loss | 2024-02-14 | At Loss |
| 2024-04-19 | At Loss | 2024-02-13 | At Loss |
| 2024-04-18 | At Loss | 2024-02-12 | At Loss |
| 2024-04-17 | At Loss | 2024-02-09 | At Loss |
| 2024-04-16 | At Loss | 2024-02-08 | At Loss |
| 2024-04-15 | At Loss | 2024-02-07 | At Loss |
| 2024-04-12 | At Loss | 2024-02-06 | At Loss |
| 2024-04-11 | At Loss | 2024-02-05 | At Loss |
| 2024-04-10 | At Loss | 2024-02-02 | At Loss |
| 2024-04-09 | At Loss | 2024-02-01 | At Loss |
| 2024-04-08 | At Loss | 2024-01-31 | At Loss |
Pharma Equity Group A/S (OCSE:PEG) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Pharma Equity Group A/S
ISIN : DK0061155009
Share Class Description:
OCSE:PEG: Class ACompare
Compare
Traded in other countries / regions
PEG.Denmark0REU.UK IPO Date
2003-06-25Description
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers